ReviewJournal of neurology2017
What's new in neuromyelitis optica? A short review for the clinical neurologist.
Review in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis.Journal of neurology · 2022Pooled it
- Neuromyelitis optica spectrum disorder: Exploring the diverse clinical manifestations and the need for further exploration.Brain and behavior · 2024Review
- Identification of neurotransmitter imbalances in the cingulate cortex of NMOSD patients using magnetic resonance spectroscopy.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- Reflections from a NMOSD case with serum AQP4-Ab negativity but CSF positivity: narrative review of how to interpret AQP4-Ab test results.Annals of translational medicine · 2023Review
- Paths to hippocampal damage in neuromyelitis optica spectrum disorders.Neuropathology and applied neurobiology · 2023Article
- Neuromyelitis Optica Spectrum Disorder: From Basic Research to Clinical Perspectives.International journal of molecular sciences · 2022Review
- Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.Journal of neurology · 2021Review
- Cognitive impairment in NMOSD-More questions than answers.Brain and behavior · 2020Review
- Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence.Journal of neurology, neurosurgery, and psychiatry · 2020Review
- Screening for cognitive impairment among patients with neuromyelitis optica using touchscreen cognitive testing in routine clinical care.Journal of neurology · 2019Article
- Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.Neurology(R) neuroimmunology & neuroinflammation · 2019Observational
- Neuromyelitis optica spectrum disorder: Patient experience and quality of life.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
- Neuromyelitis optica spectrum disorders.Clinical medicine (London, England) · 2019Review
- Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations.Neuropsychiatric disease and treatment · 2017Review
- Plasma Exchange as a First Line Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorders.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution of neuromyelitis optica spectrum disorder (NMOSD) from a rare, incurable and misunderstood disease with almost universally poor outcomes to its present state in just over a decade is unprecedented in neurology and possibly in medicine. Our knowledge of NMOSD biology has led to the recognition of wider phenotypes, new disease mechanisms, and thus clinical trials of new and effective treatments. This article aims to update readers on the recent developments in NMOSD with particular emphasis on clinical advances, the 2015 diagnostic criteria, biomarkers, imaging, and therapeutic interventions.
Indexed as
Identifiers
28289845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.